Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab safety and effectiveness study in high-risk infants in Russia and Belarus
2016-000221-39Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palivizumab in respiratory syncytial virus disease (RSV), sponsored by AbbVie Inc. Primary endpoint: RSV hospitalization.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-000221-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000221-39.